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Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide
clinical benefits over chemotherapy for lung cancer patients with EGFR activating mutations. Despite initial clinical responses, long-term efficacy is not possible
because of acquired resistance to these therapies. We have developed EGFR TKI
drug-tolerant (DT) human lung cancer cell lines as a model for de novo resistance.
Mass spectroscopic analysis revealed that the cytochrome P450 protein, CYP51A1
(Lanosterol 14α-demethylase), which is directly involved with cholesterol synthesis,
was significantly upregulated in the DT cells. Total cellular cholesterol, and more

Abbreviations: Akt, Serine-threonine protein kinase AKT1; ANOVA, Analysis of variance; Bad, BCL2 associated agonist of cell death; Bak, Bcl-2 homologous antagonist killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma extra-large; Bid, BH3 Interacting Domain Death
Agonist; Bim, Bcl-2-like protein 11; CO2, Carbon Dioxide; COX4, Cytochrome c oxidase subunit 4; CYP51A1, Lanosterol 14α-demethylase; DHCR24,
24-Dehydrocholesterol reductase; DHCR7, 7-Dehydrocholesterol reductase; DMSO, Dimethyl sulfoxide; DT, Drug-tolerant; Ebp, Delta(8)-Delta(7) sterol
isomerase; EGF, Epidermal growth factor; EGFR, Epidermal growth factor Receptor; Erk, Extracellular signal-regulated kinases; FBS, Feta Bovine Serum;
FGFR, Fibroblast growth factor receptors; FiSS, Fiber inspired smart scaffold; HER2, Human epidermal growth factor receptor 2; HMG-CoA, β-Hydroxy
β-methylglutaryl-CoA; HPRT, Hypoxanthine-guanine phosphoribosyltransferase; IC50, Half maximal inhibitory concentration; ITRAQ, Isobaric tag for relative
and absolute quantitation; JAK, Janus kinases; LDL, Low-density lipoprotein; LLC, Lewis lung carcinoma; LSS, Lanosterol Synthase; LXRs, liver X receptors;
Mapk, Mitogen-activated protein kinase; MBCD, Methyl-β-cyclodextrin; Mcl-1, Induced myeloid leukemia cell differentiation protein; Mek, Mitogen-activated
protein kinase kinase; MET, c-Met proto-oncogene protein; MOMP, Mitochondrial outer membrane permeabilization; mTor, Mammalian target of rapamycin;
mTorc2, Mammalian target of rapamycin complex 2; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; Noxa, Phorbol-12-myristate-13acetate-induced protein 1; NSCLC, Non-small-cell lung carcinoma; PARP, Poly ADP ribose polymerase; PBS, Phosphate buffered saline; PI, Propidium iodide;
PI3K, Phosphoinositide 3-kinase; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; Puma, p53 upregulated modulator of
apoptosis; Raf, Rapidly Accelerated Fibrosarcoma kinase; Ras, p21/Ras family small GTPase; SC5D, Lathosterol oxidase; SEM, Standard error of the mean;
SOAT1, Sterol O-acyltransferase; Src, Proto-oncogene tyrosine-protein kinase Src; SREBPs, Sterol regulatory element-binding proteins; Stat3, Signal transducer
and activator of transcription 3; TKI, Tyrosine kinase inhibitor; VEGFR, Vascular endothelial growth factor receptor; Wnt, Proto-Oncogene Wnt-1.
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specifically, mitochondrial cholesterol, were found to be upregulated in DT cells. We
then used the CYP51A1 inhibitor, ketoconazole, to downregulate cholesterol synthesis. In both parental and DT cells, ketoconazole and EGFR TKIs acted synergistically to induce apoptosis and overcome the development of EGFR tolerance. Lastly,
this combination therapy was shown to shrink the growth of tumors in an in vivo
mouse model of EGFR TKI resistance. Thus, our study demonstrates for the first time
that ketoconazole treatment inhibits upregulation of mitochondrial cholesterol and
thereby overcomes EGFR-TKI resistance in lung cancer cells.
KEYWORDS
cholesterol, drug tolerance, EGFR TKIs, lung cancer
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IN T RO D U C T IO N

About 20% of all non-small cell lung cancer (NSCLC) patients harbor an epidermal growth factor receptor (EGFR)
activating mutation.1 EGFR tyrosine kinase inhibitors
(EGFR-TKIs) have been shown to provide clinical benefits
over chemotherapy for lung cancer patients with EGFR activating mutations.2 Some first generation-(gefitinib, erlotinib,
lapatinib), second generation-(afatinib), and third-generation
(osimertinib) EGFR TKIs are clinically approved to treat
NSCLC patients.3 Lapatinib is a special case, as it is qualified as a dual TKI, which interrupts both the HER2 and
EGFR pathways, and is commonly used to treat patients with
metastatic breast cancer whose tumors overexpress HER2.4
Despite the initial clinical responses to EGFR targeted therapies, acquired drug resistance hampers TKI effectiveness
in most patients.1,3 Target alteration, increased ligand production, increased downstream pathway activation, and
alternative pathway activation have all been proposed as
mechanisms of resistance to EGFR TKIs.1,3 Numerous cellular signaling pathways have been implicated in EGFR TKI
resistance.1,5-17
It has been shown that statins, which work to lower cholesterol, in combination with EGFR TKIs provide additional benefits over EGFR TKIs alone. A population-based
case-control study, including 1707 statin and 6828 non-statin matched lung cancer cohorts with EGFR TKI treatment,
found that statin use was associated with a reduced risk of
death, a significantly longer median progression-free survival, and significantly longer median overall survival.18 It
has been found that a combination treatment of EGFR TKIs
and simvastatin is able to overcome T790M mediated EGFR
TKI resistance through downregulation of AKT/β-catenin
survival signaling.16 Simvastatin treatment was shown to
be able to restore expression of proapoptotic protein, BIM
and induce apoptotic cell death in H1975 cells which harbor the T790M EGFR mutation.17 Another study suggested

that a combination of lovastatin and gefitinib can overcome
resistance to gefitinib through downregulation of RAS and
inhibition of RAF/ERK and AKT.19 Two studies have found
that lovastatin induced cholesterol depletion from lipid rafts
and was able to restore sensitivity to gefitinib in resistant cell
lines.20,21 Taken together, these studies highlight the potential for a combination therapy targeting cholesterol synthesis
along with EGFR inhibition.
The lipid cholesterol, an essential component of plasma
membranes and lipid rafts, plays important roles in maintaining cellular homeostasis via intracellular signal transduction.22,23 Lipid rafts are small domains within the cell
membrane that are less fluid than the neighboring membrane due to the fact that they are enriched in cholesterol
and sphingolipids. EGFR has been shown in multiple studies to be associated with lipid rafts.24-26 In the case of EGFR
TKI activity, a few studies have been done to determine the
role of lipid rafts in the cellular responses to EGFR inhibition by TKIs.20,21 One study found that cholesterol levels in lipid rafts from gefitinib resistant NSCLC cell lines
were significantly higher than those from a gefitinib sensitive cell line.20 Another study found that EGFR localized to
cell membrane lipid rafts in EGFR TKI resistant cell lines
and that the lipid rafts were providing a platform for activation of Akt signaling even in the absence of EGFR kinase
activity.21
Another potential role for cholesterol modulation of the
EGFR pathway lies in the mitochondrial membrane and its
role in apoptosis. Human cells have two major apoptosis
signaling pathways: the extrinsic or death receptor pathway
and the intrinsic or mitochondrial pathway.27,28 The intrinsic pathway exerts its apoptotic effects via mitochondrial
outer membrane permeabilization (MOMP), the release of
cytochrome c, and activation of the caspase cascade.27,28 For
MOMP to occur, a number of Bcl-2 family proteins must
be engaged.27,28 EGFR TKIs have been shown to mediate
their apoptotic effects via the intrinsic pathway of apoptosis
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through inhibition of Akt and Erk dependent pathways that
cause changes in the expression level of Bcl-2 family members and allow for activation of apoptosis.27,28 In some cancers, enriched mitochondrial cholesterol levels have been
shown to induce resistance to apoptotic signals.29-31 Several
studies have shown that elevated levels of mitochondrial
cholesterol in cancer cells may be able to protect against mitochondrial apoptosis by changing mitochondrial membrane
dynamics and permeability.29-31 In these cases, a cholesterol-mediated decrease in mitochondrial membrane fluidity
reduces the ability of Bax to insert into the mitochondrial
membrane which impairs MOMP, and the release of cytochrome c in response to Bax.29-31 So far, however, no studies
have linked this phenomenon to EGFR TKI exposure and
resistance.
The initial mechanisms that promote survival of the
drug-tolerant (DT) cells may be sufficient to prevent apoptosis but may not fully recapitulate the oncogenic signaling provided by EGFR. These cells provide a reservoir from which
genetic mechanisms of acquired resistance can evolve.32-34
We hypothesize that a better understanding of cholesterol's
role in the mechanisms responsible for initial cell survival
after exposure to EGFR TKIs will allow us to design a therapy that is able to target these DT cells and prevent the development of drug resistance.

2

|

M AT E R IA L S A N D ME T HODS

This section presents the general molecular biology techniques used during the study.

2.1
2.1.1

|

In vitro studies

|

Amplex Red cholesterol assay

Cholesterol was extracted using a 30:20 solution of Hexane/
Isopropanol. Cholesterol content was determined using the
Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific,
) according to the manufacturer's protocol. The assay detects
both free cholesterol and cholesteryl esters. Cholesterol content was normalized to cell count and graphed as fold change
over control.

2.1.2

|

Cell culture- monolayer and scaffold

Cell lines were purchased from the American type culture
collection (ATCC) and passaged no more than 25 times.
Cells were cultured in a humidified incubator at 37C in a 5%
CO2 (Carbon Dioxide) atmosphere. Cells were cultured in
tissue culture treated plates in the appropriate complete cell

culture media [DMEM or RPMI (GE Healthcare) containing
10% fetal bovine serum (FBS) (Atlanta Biologicals) and 1%
penicillin/streptomycin (GE Healthcare)]. The Fiber Inspired
Smart Scaffold (FiSS) was prepared and seeded with cells
as previously described.35-37 Tumor derived biopsy cultures:
mice were injected subcutaneously on flanks with 3 million H1650 parental (right) and DT (left) cells. The tumors
were harvested when they reached about 10mm in diameter
and digested using MACS Miltenyi Biotec Mouse Tumor
Dissociation kit and gentle MACS Dissociator (Miltenyi
Biotec) according to the manufacturer's protocol. Tumor cell
suspensions were then plated on the FiSS just as cell line
suspensions.

2.1.3

|

Cell Titer Glo IC50 assay

Cells were treated with varying concentrations of drug for
48 hours in monolayer (duplicates) and FiSS cultures (triplicates). Drugs were added on day 5 of FiSS culture or after
24 hours of monolayer culture. Cell viability was determined
using Cell Titer Glo assay (Promega) according to the manufacturer's protocol. Luminescence was measured in a white
well-plate in a Bio-Tek Synergy H4 plate reader (BioTek).
Average luminescence value for each group was plotted as
a percentage of the control group. A non-linear regression
was then run to calculate the IC50 value. Drugs were obtained from LC Laboratories and Sigma Aldrich. 2% Lipogro
Bovine Cholesterol Concentrate was purchased from Rocky
Mountain Biologicals, Inc.

2.1.4

|

Combination index

Combination index was calculated using the formula 21:

CI =

{

[IC50 LP (at X dose KC)]
IC50 LP

} {
}
[X dose KC]
+
IC50 KC

A CI < 1 = synergy, a CI = 1 = additive effect, and a
CI > 1 = an antagonistic effect.

2.1.5

|

DT cell line generation

Lung cancer cell lines containing EGFR mutations (H1650
and H1975) in addition to EGFR wild type cell lines (H1299
and LLC1) were used to represent a range of NSCLCs
(Table 1). H1975 cells have stable expression of luciferase
and green fluorescent protein (GFP) and LLC cells have
stable expression of luciferase. These two cell lines were
purchased from Genecopoeia (Maryland USA) (H1975)
and PerkinElmer (LLC) and were grown according to the
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Lung cancer cell lines used in this study

Driver mutations
CELL LINES

SPECIES

CDKN2A

EGFR

KRAS

NRAS

PIK3CA

TP53

H1650

Human

c.1_471del471

c.2235_2249del15

WT

WT

WT

c.673-2A > G

H1975

Human

c.205G > T

c.2369C > T c.2573T > G

WT

WT

c.353G > A

c.205G > T

H1299

Human

WT

Overexpress

WT

c.181C > A

WT

Deletion

LLC

Mouse

WT

Overexpress

p.G12Chet

p.Q61Hhet

WT

WT

manufacturer's protocol. Cells were grown in appropriate
complete cell culture media containing the highest static
concentration of the respective EGFR TKI that they would
proliferate in and used for experiments from day 21 to
day 60.

2.1.6

|

Flow cytometry

All flow cytometry experiments were performed using a
Becton Dickenson Biosciences (BD) FACS Canto II system at the University of South Florida COM Fred Wright Jr
Flow Cytometry Core. All analysis and graphing for flow
cytometry experiments was done using FlowJo 8.7 software (BD).

Annexin V assay
Cells were treated with lapatinib and/or ketoconazole for
48 hours in monolayer cultures. They were then stained for
Annexin V and PI using the FITC Annexin V Apoptosis
Detection Kit I (BD Pharmingen) or the eBioscience™
Annexin V Apoptosis Detection Kit APC (Thermo Fisher
Scientific) according to the manufacturer's protocol.
JC-1 assay
Cells were treated with lapatinib and/or ketoconazole for
48 hours in monolayer cultures. They were stained with
JC-1 (Thermo Fisher Scientific) according to the manufacturer's protocol. Data was graphed as mean PE/Alexa 488
ratio.

2.1.7

|

Lipid raft staining

Cells were treated with lapatinib for 48 hours in monolayer cultures. Lipid rafts were stained for using the Vybrant™ Alexa
Fluor™ 555 Lipid Raft Labeling Kit (Thermo Fisher Scientific)
according to the manufactures’ protocol. Z-stack images (600×)
were taken using the Olympus FLUOVIEW FV1000 confocal
laser scanning microscope. Max projections of the confocal
Z-stack images (600×) were analyzed for fluorescence intensity per total cell area using ImageJ software (National Institute
of Health). Data were graphed as fold change over control.

2.1.8

|

Mass spectroscopy

Whole cell lysate for each cell line was run in duplicate.
Peptides for each sample were labeled using ITRAQ labeling kit. Data were collected using the Q Exactive Plus mass
spectrometer (Thermo Fisher Scientific) and analyzed first
using MaxQuant proteomics software (Max-Planck-Institute
of Biochemistry) and next uploaded into Scaffold software
(Proteome Software) for statistical analysis. Identified proteins were first subjected to a Mann-Whitney U test to look
for significant differences in protein abundance. Protein
abundance is measured by the average intensities between
replicates. Proteins that were identified to have a P-value of
P ≤ .05 were further analyzed to characterize the fold change
difference between the groups.

2.1.9

|

Mitochondrial isolation

Cell pellets were collected, and mitochondria were extracted
using the Mitochondria Isolation Kit for Cultured Cells (Thermo
Fisher Scientific) according to the manufacturer's protocol.

2.1.10

|

Nuc blue fluorescent microscopy

Tumoroid formation was assessed using fluorescent microscopy (EVOS, Thermo Fisher Scientific) after nuclear staining with Nuc Blue dye (Thermo Fisher Scientific) according
to the manufacturer's protocol.

2.1.11 | Quantitative reverse transcriptase
PCR (qPCR)
Total cellular RNA was extracted from cell pellets
using Trizol (Thermo Fisher Scientific) according to
the manufacturer's protocol. RNA was quantified using
the Nanodrop (Thermo Fisher Scientific). One microgram of RNA was then reverse transcribed using the
Maxima cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) according to the manufacturer's protocol. qPCR
performed on the cDNA was used to quantitate the relative
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expression levels of certain genes to hypoxanthine- guanine phosphoribosyltransferase (HPRT) or β-actin as a
control. Real time analysis was performed using BlazeTaq
SYBR Green qPCR Mix 2.0 (Genecoepia), according to
the manufacturer's protocol, in a Bio Rad CFX-384 thermocycler using primers obtained from Integrated DNA
Technologies (IDT). (See Table 2 for primer sequences).
The data were analyzed using ΔCt and ΔΔCt calculations
and expression of all genes was normalized to HPRT expression as a housekeeping gene. Average fold change
±SEM, compared to control, was then calculated. Data
analysis was performed using the CFX Maestro software
(Bio-Rad).

2.1.12

|

Western immunoassay

WES automated capillary western blotting
Total protein was extracted from cell pellets using RIPA
buffer (Thermo Fisher Scientific) according to the manufacturer's protocol. Protein concentration was determined using
the Pierce Coomassie Protein Assay Kit (Thermo Fisher
Scientific) according to the manufacturer's protocol. The
expression of the indicated proteins was determined using
the WES (Protein Simple) automated western blotting system according to the manufacturer's protocol. Total protein
expression was analyzed using area under the curve (AUC)
measurements generated using Compass software for Simple
Western (Protein Simple). Housekeeping genes were used to
quantify relative protein expression. Average AUC ± SEM as
a percentage of control was calculated. Images were derived
using Compass Software (Protein Simple). For antibodies
used: see Table 3.

TABLE 2
time PCR

Human primer sequences used for quantitative real

Gene

Strand

Primer sequence

β-Actin

Forward

CAAACATGATCTGGGTCATCTTCT

Reverse

CAAACATGATCTGGGTCATCTTCT

Forward

ACATGCTCGGCTCTCGGAC

Reverse

AGGTATAGAGCTGGGCGGCT

Forward

ATCGCAGCTTTGTGCGATG

Reverse

CACCAGGAAACCCAGCGT

Forward

GAAAGGGTGTTTATTCCTCATGG

Reverse

CAGTGCTTTGATGTAATCCAGCAG

Forward

GGCAGACGTGGACCTACC

Reverse

GAAAAGTGGGCCACCATAATC

Forward

CCCTTCAGTGCAACGGTCATTCAC

Reverse

TGCCATTGGCCGTTTGTGTC

DHCR7
DHCR24
HPRT
LSS
SREBF2

TABLE 3

Antibodies used in immunoblotting

Protein

Company

Catalog number

AKT

Cell signaling

4685

p-AKT

Cell signaling

4060

α-actinin

Santa Cruz
biotechnology

Sc-17829

β-actin

Sigma-Aldrich

A2228

Cleaved Caspase-9

Cell signaling

9501P

Cox IV

Novus biologicals

NBP2-43540

Cytochrome c

Novus biologicals

MAB897

CYP51A1

Sigma-Aldrich

HPA041325

DHCR24

Abcam

Ab40490

EGFR

Cell signaling

4267

p-EGFR

Cell signaling

3777

LSS

Abcam

Ab80364

ERK1/2

Cell signaling

4695

p-ERK1/2

Cell signaling

4370

PARP1

Cell signaling

9542

SREBP2

Abcam

Ab30682

Survivin

Cell signaling

2808

Vinculin

Santa Cruz
biotechnology

Sc-25336

Anti-Mouse

EMD millipore

2 854 655

Anti-Rabbit

Santa Cruz
biotechnology

Sc-2357

Traditional western blotting
Protein was extracted as described above. Proteins (30 μg)
were then resolved by SDS-polyacrylamide gel electrophoresis (Bio-Rad) and transferred to a nitrocellulose membrane
(Bio-Rad). Blots were blocked in PBST [PBS (Phosphate
buffered saline) plus 0.05% Tween 20 (Sigma Aldrich)] containing 5% instant milk and incubated with primary antibody
in PBST overnight at 4°Celsius. Proteins recognized by the
antibody were detected by SuperSignal™ West Pico PLUS
Chemiluminescent Substrate (Thermo Fisher Scientific) using
a horseradish peroxidase-coupled secondary antibody according to the manufactures’ protocol. Housekeeping genes were
used to determine relative protein expression. For antibodies
used: see Table 3.

2.1.13

|

Animal experiments

C57BL/6 mice were purchased from Envigo. Mice were injected subcutaneously on the flank with 1 million LLC cells.
Nu/Nu nude mice were purchased from Envigo. Mice were injected subcutaneously on the flank with 3 million H1650 cells.
Mice began treatment when tumors became palpable (2-3 mm
diameter). Mice were randomized and treated every day with
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vehicle control, 50 mg/kg lapatinib, 20 mg/kg ketoconazole,
or a combination of both until collection. Drugs were injected
intraperitoneally. Drugs were dissolved in 0.1% Tween 20
with 5% DMSO in water. Tumors were collected when controls reached about 10 mm × 10 mm. Animals were housed in
the University of South Florida comparative medicine facility
at the Morsani College of Medicine and all protocols were reviewed and approved by the USF institutional animal care and
use committee.

2.1.14

|

Statistics

Experiments have been repeated at least twice. When comparing just two groups, such as DT vs parental or treated
vs control, statistical significance for each experiment was
determined using a paired t-test for paired data, an unpaired
t-test for unpaired data, or a Mann-Whitney test when the
data were not normally distributed. When comparing multiple groups, statistical significance for each experiment was
determined using Analysis of variance (ANOVA), the Tukey
post hoc test when comparing the mean of each group with
the mean of every other group, the Bonferroni post hoc test
when comparing means of preselected groups, and a KruskalWallis test and the Dunn's post hoc test when the data were
not normally distributed. *P < .05, **P < .01, ***P < .001,
****P < .0001. Calculations were performed and graphs
were plotted using Prism 6.0 software (GraphPad). Graphs
of results show the mean and error bars depict the mean plus
or minus the standard error of the mean (SEM).

3

|

R E S U LTS

3.1 | Establishment of EGFR TKI-tolerant
cell lines
To investigate drug resistance to EGFR TKIs, we have developed lapatinib- and gefitinib-tolerant lung cancer cell lines
as models for de novo drug resistance. A comparison of drug
sensitivity using dose response curves showed that H1299and H1650-DT cells were >2-fold more tolerant to lapatinib
than parental cells, whereas H1975- and LLC-DT cells were
still significantly more tolerant than parental cells, but less
than 2-fold (Figure 1A). Using an annexin V apoptosis assay
we found that after exposure to lapatinib the percentage of
annexin V+/PI- and annexin V+/PI+ cells increased more
in H1975-parental cells compared to the -DT cells (Figure
1B). This same trend was seen when H1299-parental and
-DT cells were exposed to lapatinib (Figure S1A). We also
found that H1299 gefitinib-DT cells were significantly more
tolerant to gefitinib compared to parental cells, but less than
2-fold (Figure S1B). These results suggest that 20-60-day
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exposure to EGFR TKIs can confer a tolerance to the drugs
when compared to unexposed cells.
Two-dimensional (2D) cultures are severely limited in
their ability to mimic the three-dimensional (3D) environment of the tumor microenvironment. We have developed a
FiSS culture environment that creates a more representative
model of tumor growth and drug resistance, which resemble
in vivo tumors.35-38 We found that the FiSS platform promotes the growth of 3D tumor-like organoids (tumoroids)
(Figure 1C). Using H1650 cells grown on the FiSS culture
we observed about a 2-fold greater lapatinib-tolerance in DT
cells compared to parental cells, however, the tolerance to
lapatinib was increased in both cell types when cultured on
the FiSS compared to monolayer (Figure 1D). We are also
able to use the FiSS to grow tumor biopsies. These tumor
biopsies contain not only the cancer cells, but also the stromal
cells which are known to modulate the acquisition of drug
resistance.35 We observed about a 2.5-fold greater lapatinib tolerance in FiSS-tumoroids derived from DT-H1650
tumor biopsies compared to parental-H1650 tumor biopsies (Figure 1E). In addition, tolerance to lapatinib increased
in both H1650-parental and -DT cells when cells were cultured from tumor biopsies on the FiSS as compared to the cell
lines alone cultured on the FiSS (Figure 1E). These results
suggest that EGFR TKI-tolerance can be enhanced by the
FiSS and further increased when tumor biopsies are cultured
on FiSS providing a more accurate model of in vivo response.

3.2 | Characterization of EGFR TKItolerant cell lines
We next used the capillary electrophoresis and western blotting system, WES (Protein Simple), to determine the relative levels of EGFR, phospho-EGFR, AKT, phospho-AKT,
ERK, and phospho-ERK (Figure 1F). Overall, EGFR pathway downstream signaling was shown to be downregulated,
with total EGFR protein increased, but a decrease seen in
total AKT protein, as well as the phospho- AKT, ERK, and
EGFR proteins in H1650-DT cells compared to -parental
(Figure 1G and 1H). The electropherograms obtained from
WES used to quantify these data are contained in Figure S2AJ. Seeing no upregulation in EGFR signaling that could be
responsible for the increase in EGFR TKI tolerance, we then
conducted mass spectrometry to find alterations in the proteome of parental vs DT cells. We found over 500 different
proteins that are significantly differentially expressed in DT
cells compared to parental cultures. Table 4 lists top protein
candidates that were upregulated in the DT cells compared
to the parental cells. Cytochrome P450 CYP51A1, which is
directly involved in cholesterol synthesis, was upregulated in
DT cells compared to the parental cells.39 The protein 14-3-3
(YWHAH), which is a scaffolding protein known to function

96

|

  

HOWELL et al.

FIGURE 1 Establishment and Characterization of Acquired Lapatinib Tolerant Cell Lines. A, Lapatinib sensitivity in parental (Par) and lapatinib

DT cell lines. H1650 (N = 6), H1299 (N = 8), H1975 (N = 6), and LLC (N = 3) cells were treated the day after seeding with varying concentrations
of the lapatinib for 48 h. Average IC50 value ± SEM is shown. A paired t-test was used to determine the significance. B, Annexin V/PI staining of
parental and lapatinib DT H1975 cells after exposure to lapatinib (LP). Cells were treated the day after seeding with 20μM of lapatinib or vehicle
for 48 h (N = 2). C, H1650 cell line grown on the FiSS (100X). D, A comparison of drug sensitivity in parental and lapatinib DT H1650 cell lines
cultured on monolayer vs. FiSS. Monolayer drug sensitivity experiments were performed as described above. For FiSS drug sensitivity experiments
cells were treated on day 5 after seeding, in triplicates, with varying concentrations of the identified drug for 48 h. Average IC50 value ± SEM in
drug treated cultures on monolayer (N = 5) and the FiSS (N = 5) is shown. An unpaired t-test was used to determine the significance. E, Lapatinib
sensitivity in H1650 cell line vs tumor derived biopsy cultures on the FiSS. Drug sensitivity experiments were performed as described previously for
the FiSS. Average IC50 value ± SEM in drug treated cultures on the FiSS (N = 5) and biopsy cultures on the FiSS (N = 4) is shown. An unpaired ttest was used to determine the siignificance. F, EGFR pathway signaling protein expression in H1650 parental and lapatinib DT cells. WES automated
capillary western blotting of whole cell lysate using antibodies against the indicated proteins. G-H, The expression of proteins was determined
using area under the curve (AUC) measurements generated using Compass software for Simple Western (Protein Simple). G, Average normalized
fold change ±SEM of EGFR (N = 2), AKT (N = 3), and ERK (N = 3) in DT compared to parental, is shown. β-actin was used as a loading control
to normalize AUC measurements. An unpaired t-test was used to determine the significance. H, Average % of normalized total protein ±SEM
expression of pEGFR (N = 2), pAKT (N = 3), and pERK (N = 3) is shown. Each phospho-protein was graphed as a percent of the respective total
protein. An unpaired t-test was used to determine the significance. *P < .05, **P < .01, ***P < .001, ****P < .0001

in a wide variety of cellular processes was also upregulated
in DT cells.40-42 We found that carnitine palmitoyltransferase
(CPT1A), a mitochondrial enzyme that facilitates lipid catabolism was significantly upregulated in the H1975-DT
cells.43,44 Also upregulated in the DT cells was the enzyme,
sterol O-acyltransferase 1 (SOAT1), a key enzyme converting
endoplasmic reticulum cholesterol to cholesterol esters, allowing for storage in lipid droplets.45

3.3 | Analysis of cholesterol metabolism in
EGFR TKI-tolerant cell lines
Three of the enzymes found to be upregulated in DT cells are
directly involved in lipid and cholesterol catabolism, so we
next examined whether exposure to an EGFR TKI would lead
to an increase in total cellular cholesterol. We first looked at
enzymes involved in cholesterol synthesis, such as CYP51A1,
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TABLE 4

Selected proteins upregulated in lapatinib DT H1975
lung cancer cells compared to the parental cells
Altered proteins

Fold change

Mann-Whitney test
(P-value)

CYP51A1

2.11

.021

YWHAH

1.99

.00088

CPT1A

1.39

.021

MIC60

1.30

<.0001

SOAT1

2.09

.021

DHCR7 (7-dehydrocholesterol reductase), DHCR24 (24-dehydrocholesterol reductase), and LSS (Lanosterol synthase),
as well as the transcription factor SREBF2 (Sterol regulatory
element-binding protein 2) to determine if their expression
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was upregulated after exposure to an EGFR TKI. After
14 days of exposure to lapatinib or gefitinib, H1299 cells
showed an increase in mRNA, over untreated cells, of at least
2-fold in CYP51A1, DHCR7, and DHCR24, as well as ~ 20fold increase in SREBF2 (Figure 2A). To determine if upregulation of these enzymes is leading to an increase in cellular
cholesterol, H1299 cells were again exposed to 7.5μM of lapatinib or 15μM of gefitinib for up to 14 days. Total cellular
cholesterol was found to be increased over untreated cells,
about 2-fold in H1299-parental cells treated with lapatinib,
and about 3-fold when treated with gefitinib for 3 days, with
cholesterol levels declining to about 1.5-fold higher than untreated by 14 days of exposure to either TKI (Figure 2B).
We then examined mRNA transcript and protein levels of
CYP51A1, DHCR7, DHCR24, LSS, and SREBF2, in DT vs
parental cells. All the cell lines examined showed between a

F I G U R E 2 Upregulation of Cholesterol Metabolism in EGFR TKI Tolerant Cells. A, Gene expression in EGFR TKI treated parental cells.
H1299 (N = 3) cells were treated at seeding with 7.5 μM lapatinib (LP) or 20 μM gefitinib (Gef) for 14 d. Average fold change ± SEM, compared
to untreated, is shown. An unpaired t-test was used to determine significance. B, Cholesterol (chol) content of EGFR TKI treated parental cells.
H1299 cells were treated at seeding with 7.5 μM lapatinib or 15 μM gefitinib for the indicated number of days. Average fold change ±SEM,
compared to untreated, is shown [Parental (N = 10), LP Day 3 (N = 6), LP day 14 (N = 2), Gef Day 3 (N = 6), Gef Day 14 (N = 4)]. * refers
to comparison to day 0. # refers to comparison between two groups connected by the line. ANOVA and the Tukey post hoc test were used to
determine the significance. C, Cholesterol synthesis enzyme protein expression in H1975 parental (Par) and lapatinib DT cells. WES automated
capillary western blotting of whole cell lysate using antibodies against the indicated proteins is shown. D, The expression of CYP51A1 (N = 3),
DHCR24 (N = 3), and SREBP2 (N = 3) was determined using AUC measurements generated using Compass software for Simple Western (Protein
Simple). α- actinin was used as a loading control to normalize AUC measurements. Average normalized fold change ± SEM, compared to parental,
is shown. An unpaired t-test was used to determine the significance. E, Cholesterol content of lapatinib DT and gefitinib DT cells. Average fold
change ±SEM, compared to parental, is shown [H1299 (N = 10), H1299 DT (N = 6), H1650 (N = 6), H1650 DT (N = 6), H1975 (N = 14), H1975
DT (N = 14), LLC (N = 4), LLC DT (N = 4), H1299 (N = 8), H1299 Gef DT (N = 6)]. An unpaired t-test was used to determine the significance
F, Mitochondrial cholesterol content of lapatinib DT cells. Average fold change ±SEM, compared to parental, is shown [H1975 (N = 4), H1975
DT (N = 4), H1650 (N = 2), H1650 DT (N = 2)]. An unpaired t-test was used to determine the significance. *P < .05, **P < .01, ***P < .001,
****P < .0001, ####P< .0001
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2.5- and 5-fold increase in these genes, besides H1975, which
also showed about a 7.5-fold increase in DHCR24 (Figure
S3A). H1299 Gefitinib-DT showed about a 12.5-fold increase
in SREBF2 (Figure S3A). We then used the WES system to
examine protein levels of cholesterol synthesis enzymes in
H1975-parental and lapatinib-DT cells (Figure 2C). We found
a 2-fold increase in CYP51A1, a 1.5-fold increase in DHCR24
and LSS, and a 1.25-fold increase in SREBP2 protein levels in
lapatinib-DT cells compared to parental (Figure 2D). The electropherograms obtained from WES used to quantify these data
are contained in Figure S3B-G. As with parental cells exposed
to EGFR TKIs, H1299, H1650, H1975, and LLC lapatinib-DT
cells showed an upregulation of cholesterol 1.5-2-fold, compared to their parental cells (Figure 2E). We also found an increase in total cellular cholesterol in H1299 gefitinib-DT cells of
about 1.5-fold compared to parental cells (Figure 2E). These results show an increase in total cellular cholesterol levels, as well
as enzymes directly involved in cholesterol synthesis in both parental cells treated with EGFR TKIs and EGFR TKI-DT cells.
We next looked at how increased levels of cholesterol could contribute to increased EGFR TKI-tolerance.
A comparison of lipid raft staining of parental- and DTH1975 cells with 48 hour lapatinib treatment showed no
statistical difference between the groups (Figure S4A-B).
Since we have already shown that the EGFR pathway is
downregulated in H1650 lapatinib-DT cells and there is
no increase in lipid raft signaling caused by increased cholesterol, which would theoretically function to turn on the
EGFR pathway in DT cells, we do not think that the elevated cholesterol is contributing to an increase in lipid raft
formation and leading to EGFR TKI-tolerance in our DT
model. To determine whether an increase in mitochondrial
cholesterol could contribute to increased EGFR-TKI tolerance, we then isolated mitochondrial protein from parental and DT cells; mitochondrial isolation was verified
using COX4 as a mitochondrial marker and vinculin as a
cytoplasmic marker (Figure S5A-C). We found that in both
H1650- and H1975-DT cells mitochondrial cholesterol was
upregulated about 2-fold compared to parental (Figure 2F).

3.4 | EGFR TKI and ketoconazole
combination therapy inhibits the
development of resistance
After finding upregulation of CYP51A1, leading to increased
cellular cholesterol levels in EGFR TKI-treated cells, we next
set out to test the potential of a CYP51A1 inhibitor, ketoconazole, used in combination with EGFR TKIs to overcome
the development of EGFR TKI-tolerance.46 Addition of
20μM ketoconazole to the culture media of H1650-parental
cells, along with 6μM lapatinib, reduced the viability of
cells (Figure 3A). Ketoconazole alone at this dose was not
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very toxic to the cells (Figure S6A). In all of the lapatinibDT cell lines, the addition of ketoconazole lowered the IC50
of lapatinib in DT cells more when compared to parental
[Figure 3B (H1650), 3C (H1650 FiSS), and 3D (H1299)].
Ketoconazole was also able to lower the IC50 of gefitinib in
H1299-parental and gefitinib-DT cells (Figure 3E). We next
used the Combination Index (CI) calculation to determine the
level of synergism between EGFR TKIs and ketoconazole.21
H1650-parental and -DT cells treated with lapatinib and ketoconazole, both on monolayer and FiSS, showed a CI < 1,
which indicates that the combination acts synergistically
(Figure 3F). H1299-parental, as well as lapatinib- and gefitinib-DT cells, also showed synergistic response between the
EGFR TKIs and ketoconazole, with their CI < 1 (Figure 3F).
These data show the synergistic potential of ketoconazole
and EGFR TKI combination therapy in lung cancer cells.
We next investigated the effects of lapatinib and ketoconazole combination therapy on cellular cholesterol levels.
Ketoconazole treatment alone did not significantly decrease
cellular cholesterol levels in all cell lines tested (Figures
3G and S6A). In both H1650- and LLC-parental and -DT cells
we found that the addition of ketoconazole to lapatinib treatment was able to halt the upregulation of cholesterol levels
seen after treatment with lapatinib alone [Figure 3G (H1650)
and S6B (LLC)]. Lastly, we examined the effect of incubating H1650 cells with excess amounts of cholesterol during
exposure to lapatinib. Cholesterol is transported in a bound
complex with protein as a low-density lipoprotein (LDL) to
cells throughout the body, where it is then taken into cells and
packaged into lysosomes and separated from the LDL protein
complex into free cholesterol, which is then transported to the
cell membrane and membrane–bound organelles.22,23 Thus,
to get parental cells to take up excess cholesterol from the
cell culture media, we added 2% Lipogro Bovine Cholesterol
Concentrate to complete growth media at the time of cell
seeding for IC50 experiments. This caused the lapatinib tolerance of parental cells to increase about 7-fold, from 5.4 uM to
34 uM, compared to cells grown in complete growth media.
However, when the cholesterol depleting agent, methyl-β-cyclodextrin (MBCD), was added to the media in addition to the
Lipogro, the tolerance to lapatinib was lowered by 2-fold to
18uM (Figure 3H). These results show that increased levels
of cholesterol in the cells can lead to increased EGFR TKItolerance, which can be reversed by stopping cholesterol production or depleting cholesterol levels.

3.5 | Induction of apoptosis by the
combination therapy
Next, we determined whether the combination of lapatinib
and ketoconazole induced better cell death than either treatment alone. Using annexin V and PI staining we showed
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F I G U R E 3 Ketoconazole and EGFR TKI Therapy Overcomes EGFR TKI Tolerance by Stopping Upregulation of Cholesterol. A, Cellular
morphology after lapatinib and ketoconazole combination therapy. Parental and lapatinib DT H1650 cells were plated and treated with 12.5 μM
lapatinib (LP), 15μM ketoconazole (KC), or a combination of both. They were allowed to grow for 72 h. Bright field microscopy at 100X is shown.
B-E, Lapatinib and ketoconazole combination sensitivity in parental and DT cell lines. Cells were treated the next day after plating with varying
concentrations of the identified drug/drugs for 48 h. Monolayer and FiSS drug sensitivity experiments were performed as described previously.
Average IC50 value ± SEM on monolayer and the FiSS is shown, H1650 (N = 4) (B) H1650 FiSS (N = 3) (C), H1299 lapatinib (LP) (N = 5) (D),
and H1299 gefitinib (Gef) (N = 5) (E). ANOVA and the Bonferroni post hoc test were used to determine the significance. F, CI was calculated
for each cell line using the average IC50 values. G, Cholesterol content after lapatinib and ketoconazole combination therapy. Parental (Par)
and lapatinib DT H1650 cells were treated the day after seeding with 10 μM lapatinib, 20 μM ketoconazole, or a combination of both for 48 h.
Average fold change ±SEM, compared to untreated parental, is shown (N = 2). ANOVA and the Tukey post hoc test were used to determine
the significance. H, Lapatinib sensitivity in H1650 parental cells. H1650 (N = 3) cells were plated in complete growth media or complete growth
media containing 2% Lipogro (LPG). Cells were treated the day after seeding, in triplicates, with varying concentrations of the lapatinib for 48 h.
Dose response curve is shown. *P < .05, **P < .01, ***P < .001, ****P < .0001

that in H1650-parental and -DT cells the combination of
15μM lapatinib and 20μM ketoconazole was able to increase the levels of both annexin V positive and annexin
V/PI double positive cells over either drug by itself after
48 hours exposure (Figure 4A). This same trend was seen
in H1975-parental and -DT cells (Figure S6C). Using traditional western blotting, we found downregulation of survivin, and cleavage of both caspase-9 and PARP (Poly ADP
ribose polymerase) in H1299, H1650, and H1975 cells after
treatment with the combination therapy, whereas lapatinib
alone was unable to cause these effects (Figure 4B). These
data suggest that both parental and DT cells are undergoing

apoptosis after treatment with a combination of lapatinib
and ketoconazole.
Due to the fact that we saw an increase in mitochondrial
cholesterol levels in EGFR TKI cells, we next evaluated the
effect of the combination therapy on mitochondrial membrane potential. To measure this we used JC-1 dye, which exhibits potential-dependent aggregation in the mitochondria
and a red to green color shift caused by changes in the concentration of red fluorescent JC-1 aggregates, as mitochondrial depolarization is indicated by a decrease in red emitting
aggregated JC-1 and an increase in green emitting soluble
JC-1.47 We found a nearly 75% decrease in mitochondrial
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F I G U R E 4 Lapatinib and Ketoconazole Therapy Induces Apoptosis Through Mitochondrial Membrane Depolarization. A, Parental (Par)
and DT cells were treated the day after seeding with 15 μM lapatinib (LP), 20 μM ketoconazole (KC), or a combination of both for 48 h (N = 2).
A, Annexin V/PI staining of parental and lapatinib DT H1650 cells. B, Apoptosis proteins in parental and lapatinib DT cells. The expression
of the indicated proteins was determined using traditional western blotting. β-Actin was used as a loading control. C, JC-1 staining of parental
and lapatinib DT H1299 cells. Average PE/Alexa 488 ratio ±SEM is shown. ANOVA and the Tukey post hoc test were used to determine
the significance. D, Cytochrome C release in lapatinib DT H1299 cells after exposure to lapatinib, ketoconazole or combination. WES automated
capillary western blotting of whole cell lysate using antibodies against the indicated proteins. E, Analysis of cytosolic cytochrome C was
determined using area AUC measurements generated using Compass software for Simple Western (Protein Simple). Vinculin was used as a loading
control to normalize AUC measurements. Average normalized fold change ±SEM, compared to untreated, is shown. A Kruskal-Wallis and the
Dunn's post hoc tests were used to determine the significance. *P < .05, **P < .01, ***P < .001

membrane potential in H1299-parental and -DT cells after
48 hours of combination therapy (15 μM lapatinib and 20
μM ketoconazole) (Figure 4C). However, only in parental
cells did lapatinib alone cause a significant decrease, of
about 50% compared to control, in mitochondrial membrane
potential (Figure 4C). Depolarization of the mitochondrial
membrane can lead to the release of cytochrome C from the
mitochondria to the cytosol in cells undergoing apoptosis.27
Using the WES system, we were able to show that after treatment with 15 μM lapatinib and 20 μM ketoconazole combination therapy for 48 hours, H1299 lapatinib-DT cells had a
significant increase in cytochrome C levels in their cytosol
compared to untreated, indicating release of cytochrome C
into the cytosol (Figure 4D,E). The electropherograms obtained from WES used to quantify this data are contained
in Figure S7A-D. Taken together, we found an inhibition of
EGFR TKI-induced cholesterol upregulation and an activation of mitochondrial apoptosis after treatment with the
EGFR TKI plus ketoconazole combination therapy .

3.6 | Mouse model of acquired EGFR
TKI resistance
We then set out to develop a mouse model of acquired
EGFR TKI-DT to test our novel combination therapy. Using
an immunocompetent LLC allograft mouse model, we
were able to replicate the in vitro model of EGFR TKI-DT.
Lapatinib treatment was able to decrease tumor size at least
threefold compared to control, however the lapatinib treated
tumors steadily grew after treatment was withdrawn at day
13 (Figure 5A). We next collected the tumors and examined both total cellular cholesterol as well as cholesterol
synthesis enzymes. Using the WES capillary immunoassay
system, we examined the levels of the cholesterol synthesis enzymes CYP51A1, LSS, and DHCR24 in both control
and lapatinib treated LLC mouse tumors (Figure 5B). The
electropherograms obtained from WES used to quantify this
data are contained in Figure S8A-H. We found a threefold
increase in CYP51A1and LSS, and a twofold increase in
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F I G U R E 5 Lapatinib and Ketoconazole Combination Therapy Overcomes EGFR TKI Resistance in an in Vivo Mouse Model of NSCLC.
A, Treatment of LLC1 tumors with lapatinib. C57BL/6 mice were inoculated with LLC1 cells. Tumors were treated every day from day 6 to day 13
with vehicle control (N = 2) or 50mg/kg lapatinib (LP) (N = 4). Tumor volume ±SEM over time is shown. An unpaired t-test was used to determine
the significance. B, Cholesterol synthesis enzyme protein expression in vehicle and lapatinib (LP) treated LLC1 tumors. WES automated capillary
western blotting of whole tumor cell lysate using antibodies against the indicated proteins. C-E, The expression of CYP51A1 (N = 6) (C), LSS (N = 6)
(D), and SREBP2 (N = 3) (E) was determined using AUC measurements generated using Compass software for Simple Western (Protein Simple).
β-actin was used as a loading control to normalize AUC measurements. Average normalized fold change ±SEM, compared to vehicle treated tumors, is
shown. A Mann-Whitney test was used to determine the significance. F, Cholesterol content of vehicle and lapatinib (LP) treated LLC1 tumors. Average
fold change ±SEM, compared to vehicle treated tumors, is shown (N = 7). An unpaired t-test was used to determine the significance. G-H, Mice were
inoculated with tumor cells. Mice began treatment when tumors became palpable (2-3mm diameter) and were treated every day with vehicle control,
50mg/kg lapatinib (LP), 20mg/kg ketoconazole (KC), or a combination. Tumor volume ±SEM over time is shown. G, C57BL/6 mice (N = 5/group)
inoculated with LLC1 cells and treated. ANOVA and the Bonferroni post hoc test were used to determine the significance. H, Nu/Nu nude mice (N = 5/
group) were inoculated with H1650 cells. One group of mice that had been receiving lapatinib treatment was switched to the lapatinib and ketoconazole
combination therapy at day 28. ANOVA and the Bonferroni post hoc test were used to determine the significance. *P < .05, **P < .01

SREBP2 protein levels in lapatinib treated tumors compared
to control tumors [Figure 5C (CYP51A1), 5D (LSS), and
5E (SREBP2)]. In these tumors we also found cholesterol
levels within the lapatinib treated group to be 1.5-fold higher
than control tumors (Figure 5F). These data show that the
upregulation of cholesterol synthesis after treatment with an
EGFR TKI also occurs in an in vivo mouse model as seen
in vitro.
Lastly, we used an in vivo tumor model to determine
the effectiveness of our novel combination therapy. In LLC

tumors we found that the combination therapy significantly
inhibted tumor growth better than lapatinib alone (Figure 5G).
In H1650 tumors however, we found that only the combination
was able to decrease tumor size by about twofold compared to
control at day 41 (Figure 5H). Even switching from lapatinib
treatment alone to the combination therapy at day 26 was able
to decrease tumor size by about twofold compared to control
at day 41 (Figure 5H). These data highlight the ability of ketoconazole and EGFR TKI combination therapy to overcome
the development of EGFR TKI resistance in vivo.
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Upregulation of cholesterol synthesis in cancer has been
shown to correlate with poor prognosis in patients and
plays a role in the development of drug resistance, as overexpression of cholesterol pathway genes has been observed
in refractory tumors.23,26,48 Total cellular cholesterol was
shown to be upregulated in gefitinib resistant cells.20 In
this study, cell lines with different sensitivities to gefitinib
were used as a model of resistance. The cells were not
under exposure to gefitinib when cholesterol was isolated,
but rather they were comparing levels between the different cell lines. We provide evidence for the first time that
upregulation of cholesterol synthesis is a direct response
to EGFR TKI exposure. We also show that mitochondrial
cholesterol levels are upregulated in lung cancer cells exposed to EGFR TKIs. Moreover, by blocking mitochondrial cholesterol buildup using ketoconazole, we were able
to overcome the development of EGFR-TKI tolerance in
lung cancer cells. EGFR TKIs have been shown to mediate
their apoptotic effects via inhibition of Akt/Erk signaling,
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which downregulates anti-apoptotic Bcl-2 family proteins
that are responsible for binding and inhibiting Bax and
Bak, which once free, can cause MOMP and activate apoptotic cell death.18,20,27,28 Several studies have shown that
elevated levels of mitochondrial cholesterol in cancer cells
may be able to protect cancer cells against mitochondrial
apoptosis by reducing the ability of Bax to insert into the
mitochondrial membrane thus impairing MOMP and the
release of cytochrome c.29-31 To our knowledge, no previous studies have linked this phenomenon to EGFR TKI
exposure and resistance.
By using our models of acquired EGFR TKI resistance we
were able to study the acquisition of resistance to EGFR TKIs
in lung cancer cells and develop a combination therapy with
the potential to overcome EGFR TKI resistance. After treatment with EGFR TKI plus ketoconazole combination therapy
we found a reversal of the EGFR TKI induced cholesterol upregulation and an activation of apoptosis. Without the buildup
of cholesterol in the mitochondrial membrane the cells were
not able to resist MOMP. Thus, apoptosis was activated by
mitochondrial membrane depolarization caused by MOMP,

F I G U R E 6 Mechanism of Action. Upregulation of cholesterol is caused by induction of ER stress after EGFR TKI exposure. This is
inhibited by ketoconazole not allowing the cell to increase cholesterol levels within the mitochondrial membrane. Without this survival mechanism,
EGFR TKI exposure leads to MOMP, release of cytochrome C, and apoptosis
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leading to cytochrome c release into the cytosol and subsequent cleavage of caspase-9 and PARP, leading to cell death
in both parental and EGFR TKI-DT cells.
Ketoconazole, a potent inhibitor of CYP51A1 along with
CYP3A4, is an FDA approved broad-spectrum systemic
antifungal agent and also used in the treatment of the hormone-dependent prostate cancer, due to its ability to block
steroidogenesis.46,49,50 Ketoconazole has also been studied to
examine its cytotoxic effects when used as a single agent, and
synergistic when combined with chemotherapeutics.49-51 When
it comes to ketoconazole and EGFR TKIs, the available data
are limited. In one study, the authors examined the impact of
ketoconazole induced CYP3A4 inhibition on lapatinib pharmacokinetics.51 They found that systemic exposure to lapatinib was
significantly increased by inhibition of CYP3A4, most likely
due to the fact that CYP3A4 is the primary metabolizing enzyme for lapatinib.51 CYP3A4 is the most abundant cytochrome
P-450 expressed in human liver and it contributes to the metabolism of many drugs in use today. This may serve to at least partially explain the combination effects seen by some drugs with
ketoconazole, a potent CYP3A4 inhibitor.52 We have shown that
through the inhibition of CYP51A1, ketoconazole was able to
halt the buildup of cholesterol in the mitochondrial membrane,
resulting in the cells not being able to resist MOMP in the presence of an EGFR TKI. To our knowledge ketoconazole is not
currently being used as a treatment for any types of lung cancer.
One last question remaining is how is treatment with EGFR
TKIs is causing upregulation of cholesterol. In our model
we found upregulation of SREBP2, which is a transcription
factor that controls the transcription of cholesterol synthesis
genes.53 It has been shown that ER stress induces activation of
SREBP2 and a subsequent cholesterol accumulation in cancer
cell lines.54 EGFR TKI-treatment has been linked to the induction of ER stress response and this is one of the reasons that
patients experience diarrhea as a common side effect of EGFR
TKIs.55,56 Another study found that erlotinib-induced ER stress
signaling can promote the survival of EGFR TKI-persister
cells after exposure to erlotinib through transcriptional adaptation via an epigenetic state change.56 Taken together, these
studies highlight the possibility that EGFR TKI induced ER
stress is causing activation of SREBP2 and subsequent activation of cholesterol synthesis (Figure 6). EGFR TKI exposure
leadin to ER stress dependant induction of SREBP2 would require further testing in our model. The knowledge gained in
our studies could be useful in the future development of therapies to overcome acquired resistance to EGFR TKIs, a major
problem in patients receiving EGFR TKIs.
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In conclusion, we have created and validated a model for EGFR
TKI-resistance, successfully used this model to examine the
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mechanisms of cell survival following EGFR TKI-exposure,
and elucidated a method of overcoming this survival to eliminate development of EGFR TKI-resistance. We showed that
cellular and mitochondrial cholesterol synthesis is upregulated after exposure to EGFR TKIs. We also demonstrated
the effectiveness of a ketoconazole plus EGFR TKI combination therapy in overcoming this phenomenon. The knowledge
gained in this study could be useful in the future development
of therapies to overcome acquired resistance to EGFR TKIs.
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